Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13)

BACKGROUND: The Bruton's tyrosine kinase inhibitor ibrutinib and the proteasome inhibitor bortezomib have single-agent activity, non-overlapping toxicities, and regulatory approval in mantle cell lymphoma (MCL). In vitro, their combination provides synergistic cytotoxicity. In this investigator...

Descripción completa

Detalles Bibliográficos
Autores principales: Novak, Urban, Fehr, Martin, Schär, Sämi, Dreyling, Martin, Schmidt, Christian, Derenzini, Enrico, Zander, Thilo, Hess, Georg, Mey, Ulrich, Ferrero, Simone, Mach, Nicolas, Boccomini, Carola, Böttcher, Sebastian, Voegeli, Michèle, Cairoli, Anne, Ivanova, Vanesa-Sindi, Menter, Thomas, Dirnhofer, Stefan, Scheibe, Bernhard, Gadient, Sandra, Eckhardt, Katrin, Zucca, Emanuele, Driessen, Christoph, Renner, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10541470/
https://www.ncbi.nlm.nih.gov/pubmed/37781158
http://dx.doi.org/10.1016/j.eclinm.2023.102221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10541470/
https://www.ncbi.nlm.nih.gov/pubmed/37781158
http://dx.doi.org/10.1016/j.eclinm.2023.102221

Ejemplares similares